Skip to main content

Type 2 Diabetes News

Type 2 Diabetes is a chronic condition involving high blood sugar levels and reduced production and responsiveness to insulin.     

Twitter summary: Lilly’s new basal #insulin Peglispro superior to Sanofi’s Lantus in A1c reduction, though some potential liver safety and hypo concerns On September 4,...
On June 11, Glooko and the Joslin Diabetes Center announced the release of their HypoMap software , a cool product that really should be able to identify and help...
Back in February, the FDA proposed an update to the nutrition fact labels for food and drinks , which would be the first major update to these labels in over two decades...
How will a new “biosimilar” insulin compare to Sanofi’s Lantus?
Twitter summary: diasend system now compatible w/ more devices + fitness trackers - system available for patients free of charge! *UPDATE* On November 12, Diasend...
Looking forward to this year’s American Diabetes Association in our hometown! Plus, how we can improve health and wellness?
What can you do right now to advance diabetes advocacy? A summary from an insightful day at Masterlab.
Twitter summary: dT presents at @US_FDA on interim results for CVOT trials in #diabetes & why we can’t delay innovation In 2008, the FDA mandated that companies...
Somehow a father just knows…
In February, Johnson and Johnson announced that its SGLT-2 inhibitor for type 2 diabetes, Invokana (canagliflozin), will undergo trials as a treatment for diabetic...
Could Tidepool’s software change type 1 diabetes?
Twitter Summary: Abbott receives EU Approval to launch Freestyle Libre – updates from EASD on payment, device accuracy, design, and user experience On September 3,...
On May 20, the Diabetes Technology Society (DTS) announced the launch of a post-market blood glucose monitoring surveillance program , which will aim to assess and...
Twitter Summary: Free from fingersticks? Abbott names its Flash Glucose Monitor system the Freestyle Libre, set to launch in EU by end of 2014 On July 16, Abbott...
(S)he said what?!?
Twitter summary: Roche’s Lucentis granted “priority review” from FDA – decision by Feb. 2015, potentially 1 st ever eye medicine for diabetic retinopathy Roche recently...
(S)he said what!?
Why do we need better and more effective diabetes advocacy?
Twitter summary: BD’s new pen needle attacks #needlephobia at the source – now available at US pharmacies On August 6, BD announced the US launch of the Autoshield Duo...
What can obesity learn from seatbelts, airbags, and tobacco? Our interview with Robert Wood Johnson Foundation’s Dr. Marks.

Pages